The popularity of copyright’s blockbuster initially sparked a surge for major pharmaceutical companies, but recent shifts present a complicated scenario for shareholders. Off-patent versions are eroding profits, and https://tiannajcnx166547.jts-blog.com/39808914/sildenafil-and-big-pharma-a-precarious-investment